By: Caimen Wigington

Exploring the Role of GRIN2B Mutations in Epilepsy and Brain Development
Mutations in the GRIN2B gene, which provides instructions for making a protein that forms part of the N-methyl-D-aspartate (NMDA) receptor, are increasingly linked to epilepsy and other brain-related disorders. The NMDA receptor acts like a gate in brain cells, allowing charged particles (ions) to flow through and helping neurons communicate. This process is essential for learning, memory, and brain development. Changes in the GRIN2B can alter how this receptor works, leading to abnormal brain activity. This paper explores how GRIN2B mutations contribute to epilepsy and neurodevelopmental disorders, focusing on their role in infantile spasms (IS), diagnostic advancements, and treatment possibilities.
The NMDA receptor is a protein complex made up of multiple parts and each one plays a key role in brain signaling and development. One part of the receptor called the GluN2B subunit, is produced by the GRIN2B gene and is particularly active during early brain development (Lemke et al., 2014). Mutations in GRIN2B can either increase or decrease the receptor’s activity, disrupting normal brain function. In cases where the receptor becomes overactive (gain-of-function mutations), it can lead to too much calcium entering cells, making neurons overly excitable and more likely to cause seizures (Lemke et al., 2014). For example, mutations like p.Asn615Ile and p.Val618Gly create hyperactive channels that contribute to epileptic activity (Lemke et al., 2014; XiangWei et al., 2018).
Studies show that GRIN2B mutations account for approximately 2% of early-onset epileptic encephalopathy (EOEE) cases and up to 6% of infantile spasms in certain groups (Lemke et al., 2014). Infantile spasms involve clusters of seizures and abnormal brain wave patterns called hypsarrhythmia. If not treated early, they can cause lasting developmental problems. While most GRIN2B mutations occur spontaneously there are some inherited variants like a splice-site mutation (c.2011-5_2011-4delTC), which have been identified in milder cases, suggesting they may have reduced effects compared to de novo (new/non-inherited) mutations (Lemke et al., 2014).
GRIN2B-related disorders show a wide range of symptoms depending on the specific mutation. More severe gain-of-function mutations tend to cause profound developmental delays and drug-resistant epilepsy. For example, West syndrome, a severe form of epilepsy, is often linked to mutations in critical regions of the GRIN2B involved in forming ion channels (Lemke et al., 2014). In contrast, milder mutations like p.Arg540His may cause less severe forms of epilepsy or only intellectual disabilities, likely due to smaller changes in receptor function (Lemke et al., 2014; XiangWei et al., 2018).
Beyond epilepsy, GRIN2B mutations have also been associated with autism spectrum disorder (ASD) and schizophrenia, which shows their broader impact on brain development and behavior (Platzer et al., 2017; Hansen et al., 2021). This connection reinforces the need for research into how these mutations affect brain signaling pathways and contribute to various disorders.
Genetic testing is an important tool for diagnosing GRIN2B-related conditions. Methods like whole-exome sequencing and gene panels can help identify mutations in patients with unexplained epilepsy or developmental delays (Hansen et al., 2021). Early diagnosis allows clinicians to provide more accurate prognoses and explore treatment options tailored to specific mutations. Although genetic testing is not where it needs to be for GRIN2B right now, there have been some advancements in genetic testing as a whole such as CRISPR/Cas9 that show promising results.
Therapeutic strategies for GRIN2B disorders are still evolving. Drugs that modulate NMDA receptor activity are being studied as potential treatments for gain-of-function mutations. Memantine, a drug that reduces NMDA receptor activity, has shown some effectiveness in preclinical models (Platzer et al., 2017). However, targeting specific receptor changes remains a challenge, and more research is needed to refine these approaches.
Future research should focus on understanding how different GRIN2B mutations alter NMDA receptor function and brain signaling. Patient-derived cells and animal models can provide insights into these processes, helping researchers identify better treatments. Long-term studies are also needed to track how these disorders progress and respond to therapies.
In conclusion, GRIN2B mutations play a significant role in epilepsy, particularly infantile spasms, and other neurodevelopmental disorders. The wide range of effects caused by these mutations highlights the complex role of NMDA receptors in brain development and activity. Advances in genetic testing and emerging treatments provide hope for better management of these conditions, but further research is crucial to unlocking more effective therapies.
References:
Hansen, F., Platzer, K., & Lemke, J. R. (2021). Genetic insights into GRIN-related neurodevelopmental disorders. Frontiers in Synaptic Neuroscience
Hu, C., Chen, W., Myers, S. J., Yuan, H., & Traynelis, S. F. (2019). Human GRIN2B variants in neurodevelopmental disorders. Journal of Pharmacological Sciences
Kang, J. Q., Shen, W., & Macdonald, R. L. (2014). Structural and functional changes in NMDA receptors linked to epilepsy. Epilepsia
Lemke, J. R., Geider, K., Helbig, K. L., Heyne, H. O., Schutz, H., Hentschel, J., Courage, C., Depienne, C., Nava, C., Heron, D., Møller, R. S., Hjalgrim, H., Lal, D., Neubauer, B. A., Nürnberg, P., Thiele, H., Kurlemann, G., Arnold, G. L., Bhambhani, V., … Helbig, I. (2014). Delineating the GRIN1 phenotypic spectrum: A distinct genetic NMDA receptor encephalopathy. Neurology
Marwick, K. F., Skehel, P. A., Hardingham, G. E., & Wyllie, D. J. A. (2023). GRIN2B mutations in epilepsy and neurodevelopment: Emerging insights. Epilepsia
Oguro, K., Oguro, N., & Kojima, T. (2016). GRIN2B mutations and their role in neurological disorders. Brain and Development
Platzer, K., Yuan, H., Schütz, H., Winschel, A., Chen, W., Hu, C., Kusumoto, H., Heyne, H. O., Helbig, K. L., Tang, S., Willing, M. C., Tinkle, B. T., Adams, D. J., Depienne, C., Keren, B., Mignot, C., Frengen, E., Strømme, P., Biskup, S., … Lemke, J. R. (2017). GRIN2B encephalopathy: Novel findings on phenotype, variant clustering, functional consequences and treatment aspects. Journal of Medical Genetics
XiangWei, W., Jiang, Y., & Yuan, H. (2018). De novo mutations and rare variants occurring in NMDA receptors: Insights into the molecular mechanisms underlying neurological disorders. Frontiers in Molecular Neuroscience